Dailypharm Live Search Close

Takeda, “Alunbrig improved both OS and QoL”

By | translator Alice Kang

21.07.07 17:39:07

가나다라 0
Enters market as the third 2nd generation ALK TKI…despite being a latecomer, makes way into market fast approved as 1st line with reimbursement

Independent review committee assessment… “significant effect in patients with brain metastasis”

Demonstrated improvement in quality of life in younger patients…holds strength with its convenience in administration

Medical Science Liaisons (MSLs) in Medical Affairs of pharmaceutical companies act as a ‘bridge’ between healthcare professionals and companies. They gather the unmet needs of HCPs and establish strategies for new drugs to address such needs. MSLs also deliver academic data and expertise based on clinical grounds in compliance with local regulations to HCPs, patients, and internal employees.

Competition has been fierce in the non-small cell lung cancer treatment market, particularly the ALK targeted therapy market, with the introduction of various new drugs. The market is moving on from the one-and-only 1st generation treatment, Pfizer’s ‘Xalkori,’ to 2nd generation products. By order of entry, three

(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)